GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

Diabetes, Obesity and Metabolism

Volumn 13, Issue 11, 2011, Pages 990-1000

  Jolivalt, C G ^a   Fineman, M ^a,b   Deacon, C F ^c   Carr, R D ^d,e   Calcutt, N A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NOVO NORDISK A S   (Denmark)

^e Sharp and Dohme A S   (Denmark)

Author keywords

Diabetes; Exenatide; Extracellular signal regulated kinase; Glucagon like peptide 1; Glucagon like peptide 1 receptor; Mice; Neuropathy; Pancreas; Peripheral nerve; Rat

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; INCUBATION TIME; MOTOR NERVE CONDUCTION; MOUSE; NERVE CELL; NERVE FIBER; NERVE FUNCTION; NERVE INJURY; NONHUMAN; PERIPHERAL NERVE; PROTEIN PHOSPHORYLATION; RAT; SCHWANN CELL; SCIATIC NERVE; SIGNAL TRANSDUCTION; SPINAL GANGLION; STREPTOZOCIN DIABETES; VELOCITY; WESTERN BLOTTING;

EID: 80053409431     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01431.x     Document Type: Article

References (47)

1. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
2. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
3. Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
4. Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 2003; 3: 3.
5. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009; 5: 266-275.
6. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996; 19: 580-586.
7. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-1322.
8. Valverde I, Merida E, Delgado E, Trapote MA, Villanueva-Penacarrillo ML. Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 1993; 132: 75-79.
9. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 1994; 37: 1163-1166.
10. Villanueva-Penacarrillo ML, Delgado E, Trapote MA et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 1995; 146: 183-189.
11. Peak M, Rochford JJ, Borthwick AC, Yeaman SJ, Agius L. Signalling pathways involved in the stimulation of glycogen synthesis by insulin in rat hepatocytes. Diabetologia 1998; 41: 16-25.
12. Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva-Penacarrillo ML. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003; 204: 43-50.
13. Brubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 2010; 151: 1984-1989.
14. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010; 123: S19-27.
15. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302: 881-888.
16. Perry T, Lahiri DK, Chen D et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002; 300: 958-966.
17. Perry T, Lahiri DK, Sambamurti K et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003; 72: 603-612.
18. Bertilsson G, Patrone C, Zachrisson O et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86: 326-338.
19. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010; 5: 109-117.
20. Martin B, Golden E, Carlson OD et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009; 58: 318-328.
21. Perry T, Holloway HW, Weerasuriya A et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007; 203: 293-301.
22. Calcutt NA. Modeling diabetic sensory neuropathy in rats. Methods Mol Med 2004; 99: 55-65.
23. Beiswenger KK, Calcutt NA, Mizisin AP. Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett 2008; 442: 267-272.
24. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 2008; 56: 841-851.
25. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-224.
26. Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol 2011 [Epub ahead of print].
27. Burcelin R, Dejager S. GLP-1: What is known, new and controversial in 2010? Diabetes Metab 2010; 36: 503-509.
28. Vahl TP, Tauchi M, Durler TS et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007; 148: 4965-4973.
29. Li Y, Duffy KB, Ottinger MA et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010; 19: 1205-1219.
30. Li Y, Perry T, Kindy MS et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106: 1285-1290.
31. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 2008; 41: 35-44.
32. List JF, He H, Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Pept 2006; 134: 149-157.
33. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillje HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010; 30: 1407-1414.
34. Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010; 325: 26-35.
35. Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403.
36. Fernandez J, Valdeolmillos M. Glucose-dependent stimulatory effect of glucagon-like peptide 1(7-36) amide on the electrical activity of pancreatic beta-cells recorded in vivo. Diabetes 1999; 48: 754-757.
37. Fernyhough P, Gallagher A, Averill SA et al. Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 1999; 48: 881-889.
38. Purves T, Middlemas A, Agthong S et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001; 15: 2508-2514.
39. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 2005; 31: 151-174.
40. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009; 8: 417-429.
41. Calcutt NA, Allendoerfer KL, Mizisin AP et al. Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy. J Clin Invest 2003; 111: 507-514.
42. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 2009; 40: 536-544.
43. Johnson MS, Ryals JM, Wright DE. Early loss of peptidergic intraepidermal nerve fibers in an STZ-induced mouse model of insensate diabetic neuropathy. Pain 2008; 140: 35-47.
44. Malmberg AB, Mizisin AP, Calcutt NA, von Stein T, Robbins WR, Bley KR. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain 2004; 111: 360-367.
45. Tesfaye S, Boulton AJ, Dyck PJ et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33: 2285-2293.
46. Ji RR, Gereau RWT, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009; 60: 135-148.
47. Subramaniam S, Unsicker K. ERK and cell death: ERK1/2 in neuronal death. FEBS J 2010; 277: 22-29.